Gastroenterology Research & Clinical Trials

About
Contact

Norton Healthcare Gastroenterology is at the forefront of gastrointestinal treatment research. As investigators on numerous trials, our specialist physicians have unparalleled experience with many innovative treatments once they are approved for broad use. Patients also may be eligible to take part in these experimental gastrointestinal treatments. Norton Healthcare Gastroenterology researchers also contribute to groundbreaking studies and other publications in peer-reviewed journals.

Learn more about participating in a clinical trial at Norton Healthcare.

Current Gastroenterology Clinical Trials and Studies

Biliary Tract Cancer

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

GI-NCIResearch@nortonhealthcare.org

Sponsor: NuCana, plc

Esophageal Cancer

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center International Study of Durvalumab Given Concurrently with Definitive Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

Eligibility Criteria and Other Details

GI-NCIResearch@nortonhealthcare.org

Sponsor: AstraZeneca

Gastric Cancer

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant/Adjuvant Durvalumab and Standard Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and astroesophageal Cancer (GC/GEJC)

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

GI-NCIResearch@nortonhealthcare.org

Sponsor: AstraZeneca

Gastric Cancer

A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC)

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

Eligibility Criteria and Other Details

GI-NCIResearch@nortonhealthcare.org

Sponsor: Seattle Genetics, Inc

Hepatocellular Carcinoma (HCC)

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)

Study Type: Drug Study

Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology

Recently published research

Sponsor: Merck Sharp & Dohme CORP

Metastatic Colorectal Cancer

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

Sponsor: Merck & Co., Inc

Metastatic Esophageal Carcinoma

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

Sponsor: Merck Sharp & Dohme CORP

Pancreatic Cancer

A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma

Study Type: Device Study

Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology

Recently published research

Eligibility Criteria and Other Details

mary.healey@louisville.edu

Sponsor: AngioDynamics, Inc.